Core Insights - Zhao Yan, known as the "Hyaluronic Acid Queen," has built a significant business empire and holds a crucial position in the capital market and industry [2] - The journey of Zhao Yan from a university assistant to a successful entrepreneur is marked by challenges and strategic decisions that led to her current success [2][3] Early Career and Initial Ventures - Zhao Yan was born in 1966 in Kunming, Yunnan, and showed exceptional academic talent, leading her to East China Normal University [2] - After graduating in 1986, she worked as a teaching assistant with a modest salary of less than 100 yuan per month [2] - In 1988, she left her stable job to pursue opportunities in Hainan, pooling 5,000 yuan with three other teachers to start a business [2][3] First Major Success - Zhao Yan discovered an opportunity with a joint venture factory in Hainan that had unsold refrigerators, which she and her partners repaired and sold, earning a profit of 800,000 yuan [3] - This initial success allowed them to invest in a clothing factory, which generated annual revenue of 1 million yuan [5] Real Estate Investments - Recognizing the potential in Hainan's real estate market, Zhao Yan used profits from the clothing business to acquire properties, leading to a wealth increase from 800,000 yuan to 2 million yuan [5] - She eventually sold her real estate holdings at the peak of the market, successfully avoiding the subsequent market crash [8] Expansion to Beijing and Real Estate Development - After relocating to Beijing, Zhao Yan founded Huaxi Group and developed significant projects, including Huaxia Bank Tower and Wukesong Sports Center, contributing to the company's total assets exceeding 80 billion yuan [9] Entry into Biopharmaceuticals - In the early 2000s, Zhao Yan invested in Shandong Furuida Biological Chemical Co., becoming the largest shareholder and later rebranding it as Huaxi Biological [11] - Under her leadership, the company became the world's largest producer of hyaluronic acid by 2007, expanding into medical aesthetics and functional skincare products [12] Product Diversification and Market Expansion - Huaxi Biological launched various medical aesthetic products, including hyaluronic acid fillers and functional skincare lines, achieving high market share and positive consumer reception [12][13] - In 2021, the company introduced functional foods like hyaluronic acid drinking water, capitalizing on the growing health-conscious consumer trend [15] Cultural and Social Contributions - Zhao Yan's leadership extended to cultural projects, such as the development of Wukesong Sports Center, which hosted major events like the 2008 Beijing Olympics [15] - The establishment of Huaxi International Era Art Museum has contributed significantly to the promotion of Chinese cultural and artistic endeavors [16] Future Outlook - Huaxi Biological stands at a new crossroads with a leading position in hyaluronic acid production, a growing skincare brand portfolio, and ambitious plans in synthetic biology [18] - Zhao Yan faces ongoing challenges in balancing marketing, technology, and corporate responsibilities as the leader of a public company [18]

/ R X ► the works of the state of the control of the country of 图/IC 指数样本定期调整，白云山、华熙生物等被调出 日前，上交所与中证指数有限公司宣布，将调整上证50、科创50、沪深300、中证500等指数样本，调整方案将于6月13日收市后生效。同期，深交所及其全 资子公司深圳证券信息有限公司宣布，将对深证成指、创业板指、深证100等指数实施样本定期调整，调整方案将于6月16日正式实施。 据了解，多数指数样本每半年调整一次，调整实施时间分别为每年6月和12月的第二个星期五的下一交易日。在定期调整时，会根据样本空间内股票的市 值、流动性等指标重新筛选成分股，将不符合要求的股票调出指数，同时选取符合条件的其他股票调入指数。 贝壳财经记者梳理发现，此次样本调整涉及多只医药生物股。比如，上证180指数更换18只样本，其中，白云山、益丰药房、华熙生物等个股被调出。沪深 300指数更换7只样本，华兰生物被调出。 中证500指数更换的50只样本中，亿帆医药、安科生物、三星医疗、九洲药业、金域医学、百克生物、荣昌生物等多只生物医药相关个股被调出，百济神 州、康 ...

Core Viewpoint - The ongoing controversy surrounding the collagen product from Juzhibio's brand Kefu Mei highlights a significant conflict between two major players in the medical beauty industry, Juzhibio and Huaxi Biological, which may represent a deeper technical rivalry between recombinant collagen and hyaluronic acid [1][2]. Group 1: Company Actions and Responses - Juzhibio confirmed that its Kefu Mei Human-like recombinant collagen essence contains more than 0.1% recombinant collagen, countering claims made by beauty blogger "Big Mouth Doctor" that the actual content was only 0.0177% [1]. - Following the allegations, Huaxi Biological publicly supported the claims made by the beauty blogger, escalating the conflict between the two companies [1]. - The dispute has led to a series of emotional exchanges between the companies, with accusations of malicious competition and misinformation being exchanged [2]. Group 2: Consumer Concerns and Industry Implications - Consumers are primarily concerned about the quality and compliance of the medical beauty products rather than the corporate disputes, indicating a need for clarity and assurance regarding product safety [2]. - The controversy has overshadowed scientific standards, with conflicting reports and a lack of consensus on the testing methods used, leading to confusion among consumers [2][3]. - The ongoing conflict reflects deeper issues within the medical beauty industry, such as unclear product standards and marketing boundaries, which have allowed for such disputes to arise [3]. Group 3: Regulatory and Industry Response - The situation calls for neutral arbitration from regulatory bodies to investigate the claims and provide credible testing reports to resolve the dispute and restore consumer trust [2]. - The market regulatory authorities have issued guidelines to strengthen oversight of the medical beauty industry, aiming to address long-standing issues such as false advertising and lack of transparency [3]. - This public incident could serve as an opportunity for the industry to establish clearer standards and regulations, ultimately benefiting both the sector and consumers [3].

文 | 新浪财经 徐苑蕾 近几年，凭借核心护肤品牌可复美，巨子生物的业绩节节攀升， 2024 年可复美品牌贡献 45.4 亿元，营收占比达到 82% 。然而，巨子生物也多次因产品成分陷入争议，舆论风波 使得公司的品牌公信力受到严峻考验。 近日，业内两大巨头 —— 巨子生物与华熙生物因 " 重组胶原蛋白 " 真实含量问题爆发激 烈争议，从产品成分质疑升级至公开 " 商战 " 。在 618 大促的关键节点，涉事产品可复 美 " 胶原棒 "1.0 版本已在多个电商平台下架。 随着事件进一步发酵升级，背后隐藏的技术路线之争与行业标准缺失问题也浮出水面。一位 化妆品行业人士直指，巨子生物和华熙生物的"开撕"，本质是两家企业对市场份额和行业 主导权的争夺。 昨晚，巨子生物发布最新回应，并公布了多家权威检测机构的检测数据：经多个检测机构对 多批次"胶原棒"进行检测分析，确认产品中重组胶原蛋白含量均大于 0.1% 。巨子生物强 调，可复美相关产品不存在 " 虚假宣传 " 的行为。同时，可复美胶原棒 1.0 版本因售罄陆 续下架，并非网传的 " 悄悄下架 " 。 检测报告引爆争议， 国内医美行业正经历一场 " 成分风暴 " 。 ...

Core Viewpoint - The domestic medical beauty industry is experiencing a "component storm," highlighted by a fierce dispute between two major players, Giant Bio and Huaxi Bio, over the actual content of "recombinant collagen" in their products, escalating from product composition doubts to a public "business war" [2][3] Group 1: Industry Dispute - The controversy was ignited by a report from Dr. Hao Yu, which claimed that the recombinant collagen content in Giant Bio's product was only 0.0177%, significantly below the stated level of over 0.1% [3] - Giant Bio responded by asserting that the accusations were "seriously inaccurate" and provided self-test results confirming compliance with standards [3][5] - Huaxi Bio publicly supported Dr. Hao and accused Giant Bio of using online tactics to manipulate public perception, escalating the conflict [5] Group 2: Market Impact - Following the dispute, regulatory authorities in Shaanxi Province initiated an investigation, and the stock market reacted with Giant Bio's shares dropping approximately 13% while Huaxi Bio's shares rose about 9.8% [6] - The market's focus on recombinant collagen has surged, with a report indicating a compound annual growth rate of 63% from 2017 to 2022, and an expected growth rate of 42.4% from 2022 to 2027, reaching 108.3 billion [9] Group 3: Financial Performance - Despite the controversies, Giant Bio's performance remains strong, with a projected revenue of 55.39 billion in 2024, a 57% year-on-year increase, and a net profit of 20.62 billion, up 42% [11] - The brand Kefu Mei contributed 45.4 billion to revenue, accounting for 82% of total sales, but the company faces risks due to its heavy reliance on this single brand [11][14] Group 4: Industry Standards - The dispute highlights the lack of unified testing standards for recombinant collagen, leading to significant discrepancies in results from different testing institutions [10] - The National Medical Products Administration has initiated the establishment of industry standards for recombinant collagen testing methods, indicating a move towards regulatory improvement [10]

Core Viewpoint - The controversy surrounding the collagen products from Juzi Biotechnology has escalated into a public relations battle, primarily initiated by Dr. Hao Yu, a skincare influencer and former chemist, who accused the company of serious fraud regarding their recombinant collagen products [1][2][4]. Group 1: Key Players - Dr. Hao Yu, known as "Big Mouth Doctor," is a skincare influencer with millions of followers and a background in chemistry, having worked in cosmetic research for 19 years [2]. - Juzi Biotechnology is a biotech company specializing in the beauty industry, known for its recombinant collagen products, which have seen a significant market cap drop of over 100 billion, leaving it with a valuation of around 700 billion [2]. - Huaxi Biotechnology, a leading player in the A-share medical beauty sector, primarily focuses on hyaluronic acid products [3]. Group 2: Allegations and Responses - Dr. Hao Yu has accused Juzi Biotechnology of serious fraud, claiming that their recombinant collagen is undetectable, marking his second round of accusations [4][11]. - In response to the allegations, Juzi Biotechnology quickly issued a consumer notice denying all accusations of fraud and asserting that their products contain collagen levels above 0.1% [13][14]. - Juzi Biotechnology stated that they conducted multiple tests to confirm the collagen content and promised to release third-party testing results to alleviate consumer concerns [14]. Group 3: Testing Methods and Controversies - Dr. Hao Yu utilized High-Performance Liquid Chromatography (HPLC) for his testing, which he claims provides a more accurate measurement of collagen content compared to Juzi's methods [16][19]. - Juzi Biotechnology's testing method was revealed to be the Biuret test, which Dr. Hao Yu criticized for potentially yielding inflated results [32][36]. - The lack of standardized testing methods for recombinant collagen has been highlighted as a significant issue, leading to confusion and disputes over product efficacy [19][20]. Group 4: Market and Consumer Reactions - The public reaction has been mixed, with some consumers expressing outrage over potential deception, while others remain supportive of Juzi Biotechnology [45][48]. - The controversy coincided with a major shopping event, leading to increased consumer anxiety regarding the products [11]. - The involvement of various influencers and the emergence of coordinated online narratives have raised questions about the authenticity of public sentiment and potential manipulation [50][51]. Group 5: Regulatory and Industry Implications - The incident has drawn attention from regulatory bodies, with local market supervision authorities beginning to investigate the claims and counterclaims made by both parties [91]. - A high-profile seminar on testing methods for recombinant collagen was held, featuring prominent experts, indicating the industry's recognition of the need for clearer standards [57][60]. - The ongoing dispute may lead to broader discussions about product transparency and consumer protection within the beauty and biotech industries [84][92].

Market Overview - The A-share market experienced a collective rise, with nearly 4,000 stocks increasing in value, indicating a strong bullish sentiment [3] - The innovation drug, beer, and beauty care sectors saw significant gains, while logistics and airport shipping faced declines [3] Sector Analysis Innovation Drugs - The innovation drug sector surged due to faster approval processes, with a 30% increase in efficiency compared to three years ago, leading to improved profit margins [4] - Major pharmaceutical companies are entering collaborations, such as Bristol-Myers Squibb's $11.1 billion partnership for cancer drugs, indicating the sector's growing international presence [4] Beer - The beer sector's growth is attributed to seasonal demand as summer approaches, alongside government policies stimulating consumption through vouchers [5] - The beer market typically experiences a short-term surge lasting two to three months, suggesting a need for cautious investment strategies [5] Beauty Care - The beauty care sector is thriving, with cosmetic retail sales growing by 9.8% year-on-year, outpacing overall consumption growth [6] - Companies are shifting towards offline differentiated competition, such as experiential stores and customized services, enhancing customer engagement [6] Downward Trends Logistics and Airport Shipping - The logistics sector faced significant declines, particularly New Ning Logistics, due to increased tariffs on steel and aluminum affecting import and export logistics [7] - The airport shipping sector is under pressure from rising fuel costs and slower-than-expected recovery of international routes [7] Investment Strategies Innovation Drugs - Investors are advised to focus on companies with substantial R&D investments, specifically those with R&D expenses exceeding 30% of revenue, to identify long-term holdings [8] Beer - The beer market requires a quick entry and exit strategy, with a recommendation to monitor the five-day moving average for trading decisions [9] Beauty Care - The beauty care sector's opportunities lie in the transition from online to offline sales, with a focus on companies with core technologies, such as patented products [11]

Core Viewpoint - The ongoing controversy surrounding Juzhi Biotechnology's alleged product fraud has escalated into a significant conflict within the medical aesthetics industry, involving major players like Huaxi Biotechnology and self-media influencer Gao Yu [1][3]. Group 1: Incident Development - The scandal began with allegations of Juzhi Biotechnology's collagen product being falsely represented, leading to a public dispute with Gao Yu, who claimed the product contained only 0.0177% of the required collagen, below the legal threshold of 0.1% [4][9]. - On May 30, the testing agency that supported Gao Yu retracted its report, which Juzhi interpreted as an apology, while still contesting the validity of Gao Yu's testing methods [2][3]. - The controversy has prompted other companies in the industry to begin testing their products, with over 100 samples submitted for testing by nine different companies [7]. Group 2: Industry Impact - The product in question, "Kefumei Human-Like Recombinant Collagen Essence," has been a core revenue driver for Juzhi, generating approximately 4.542 billion yuan in revenue in 2024, accounting for about 82% of the company's total revenue [9]. - Huaxi Biotechnology's involvement has intensified the situation, as they publicly supported Gao Yu and criticized the tactics used by Juzhi, suggesting a broader industry conflict [12][15]. - Following Huaxi's announcement, their stock rose by 6.94%, while Juzhi's stock fell by 4.69%, reflecting the market's reaction to the unfolding drama [16].

Core Viewpoint - The controversy surrounding the collagen content in the product "Kefumei" from Giant Biological has raised significant consumer and investor concerns, with ongoing debates about the accuracy of testing methods and results [1][10]. Group 1: Testing Results - Giant Biological confirmed that the "Kefumei Human-like Recombinant Collagen Essence" contains recombinant collagen, with content levels greater than 0.1% as per third-party testing [2][10]. - The testing utilized two methods: LC-MS/MS for qualitative analysis and the Biuret method for quantitative analysis, with results showing collagen content of 0.2%, 0.22%, and 0.2% across three batches [2][8]. - A subsequent test on one batch indicated a collagen content of 0.17%, confirming that the product meets the stated requirements [8][9]. Group 2: Consumer Concerns and Responses - The initial claim by beauty blogger "Big Mouth Doctor" suggested that the actual collagen content was only 0.0177%, leading to widespread skepticism about the product's integrity [10][11]. - Giant Biological emphasized that there is no misleading advertising and that the product has been properly tested, countering claims of "quietly delisting" the product due to sales issues [10][11]. - The company expressed concern over consumer anxiety caused by misinformation and reiterated its commitment to transparency and product integrity [10][11]. Group 3: Industry Reactions - Huaxi Biological publicly supported the claims made by "Big Mouth Doctor," indicating that they have conducted their own evaluations and testing of the product [11][14]. - Huaxi Biological criticized Giant Biological for alleged unethical marketing practices and indicated readiness to engage in a public discourse regarding product integrity [14][15].

华熙生物的下场无疑将"战况"再度升级，叠加此前，华熙生物炮轰"玻尿酸过时论"，华熙生物的此番下场战队，也被市场解读为是护肤成分市场中玻尿酸与 重组胶原蛋的路线之争。 出品｜搜狐财经 作者｜冯圆圆 端午假期期间，巨子生物产品造假风波再度升级。 6月1日晚间，华熙生物发文表示支持大嘴博士维护消费者权益；同时，已对大嘴博士发来的相关资料进行评估和第三方测试，且已得到结果。并表示，在其 公布结果之前，希望相关企业主动面对问题。 另一方面，巨子生物也在3小时后，发布了机构的道歉声明，同时表示对某上市公司的发言感到震惊又痛心。 一来一往，双方的发言均将矛头指向了对方。 可复美造假事件再升级 6月2日，知名大V大嘴博士再度发文"炮轰"巨子生物，剑指巨子生物对其合作的检测机构施压；同时表示，自己已联系不到当时负责检测的负责人。 （图片来源：大嘴博士颜究所） 大嘴博士的此番言论，再度将双方的"骂战"升级。 回顾时间线，5月24日，知名大V大嘴博士在微博发布了一则8分钟的视频，直指巨子生物旗下大单品可复美胶原蛋白精华的胶原蛋白含量造假。 （图片来源：大嘴博士微博） 据大嘴博士表示，巨子生物大单品可复美胶原蛋白精华中重组胶原蛋白的 ...